Application of combination of VEGFR inhibitor and anti-PD-1 antibody in preparation of medicine for treating pregnancy trophoblastic tumor

A trophoblast and PD-1 technology, applied in the direction of anti-tumor drugs, antibody medical components, antibodies, etc., can solve the problems of undisclosed VEGFR inhibitors

Pending Publication Date: 2021-05-04
JIANGSU HENGRUI MEDICINE CO LTD +2
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] WO2018068691A discloses the use of an anti-PD-1 antibody combined with a VEGFR inhibitor in the preparation of a drug for the treatment of cancer. The VEGFR inhibitor can be selected from apatinib mesylate or a pharmaceutically acceptable salt thereof. The cancers mentioned above can be selected from breast cancer, lung cancer, gastric cancer, kidney cancer, liver cancer, melanoma, etc., but it is not disclosed whether the combination of VEGFR inhibitor and anti-PD-1 antibody can be used to treat gestational trophoblastic tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1. Efficacy and safety of PD-1 antibody combined with apatinib mesylate in the treatment of recurrent / drug-resistant gestational trophoblastic tumor

[0068] 1. Experimental drugs

[0069] PD-1 antibody: commercially available camrelizumab for injection, 200mg, freeze-dried powder;

[0070] Apatinib: Apatinib mesylate tablets are commercially available.

[0071] 2. Enrolled subjects

[0072] All of the following inclusion criteria must be met to be eligible for entry into this trial.

[0073] (1) Drug-resistant / relapsed GTN patients who have failed at least two or more combined chemotherapy regimens;

[0074] (2) 2000 FIGO trophoblastic tumor prognostic score ≥ 7 points (high-risk GTN patients) or drug-resistant or recurrent epithelioid trophoblastic tumor or placental site trophoblastic tumor;

[0075] (3) 18-70 years old;

[0076] (4) The patient's ECOG score is 0-2 points;

[0077] (5) Abnormal blood HCG levels and / or clinically evaluable lesions accord...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of combination of a VEGFR inhibitor and an anti-PD-1 antibody in preparation of a medicine for treating pregnancy trophoblastic tumor. Specifically, the anti-PD-1 antibody involved in the disclosure is a humanized antibody, and the VEGFR inhibitor involved in the disclosure is selected from tafetinib, kanitinib, apatinib and the like or pharmaceutically acceptable salts thereof.

Description

technical field [0001] The disclosure relates to the use of a VEGFR inhibitor in combination with an anti-PD-1 antibody in the preparation of a drug for treating gestational trophoblastic tumor. Background technique [0002] Gestational trophoblastic disease (GTD) is a type of placental trophoblastic disease. According to its histomorphological characteristics, it can be divided into mole, invasive mole, placental site trophoblastic tumor, and choriocarcinoma, among which invasive mole (IM), choriocarcinoma (CC), placental site trophoblastic tumor, etc. Placental site trophoblastic tumor (PSTT) and epithelial trophoblastic tumor (ETT) are collectively called gestational trophoblastic neoplasm (GTN). [0003] Epidemiological surveys in my country show that the incidence of mole pregnancy is 0.81‰ (calculated in thousands of pregnancies); in recent years, the incidence of mole pregnancy has decreased, which may be due to the improvement of economy and diet and the decline of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K39/395A61P35/00A61K31/444
CPCA61K45/06A61K31/444A61K39/39566A61K39/39558A61P35/00A61K2300/00
Inventor 向阳杨隽钧程红燕
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap